Stage 1A cancer means a small tumor that has not spread to lymph nodes or other parts of the body. It represents one of the earliest points at which cancer can be diagnosed, and it generally carries a favorable prognosis. The exact size thresholds and definitions vary by cancer type, but the underlying principle is the same: the cancer is small, contained, and has not begun to migrate.
How the Staging System Works
Cancer staging uses a system called TNM, which stands for Tumor size, Node involvement, and Metastasis. Stage 1A across nearly all cancer types is classified as T1, N0, M0. That translates to a small primary tumor (T1), no cancer in nearby lymph nodes (N0), and no spread to distant organs (M0). The “A” in Stage 1A typically distinguishes it from Stage 1B by tumor size or depth of invasion, with 1A being the smaller or shallower of the two.
Because different organs have different anatomies, the specific measurements that qualify as “small” depend on where the cancer is. A 2-centimeter tumor is the upper limit for Stage 1A breast cancer, while a 4-centimeter tumor can still qualify as Stage 1A in the kidney. The sections below break down the most common cancer types.
Stage 1A in Breast Cancer
In breast cancer, Stage 1A means the tumor is 2 centimeters or smaller, roughly the size of a peanut, and has not spread to the lymph nodes. This is one of the most commonly diagnosed early-stage cancers, often caught through routine mammography before a lump is noticeable by hand.
Recurrence risk depends heavily on tumor size within this stage. A study following 382 women with Stage I breast tumors found that those with tumors 1 centimeter or smaller had a recurrence rate of just 7% over ten years. For tumors between 1.1 and 2 centimeters, recurrence rose to 21%. Certain tumor subtypes, including tubular, medullary, and colloid carcinomas up to 2 centimeters, also carried very low recurrence risk.
Stage 1A in Lung Cancer
Lung cancer has the most granular breakdown of any Stage 1A classification, splitting it into three sub-stages based on tumor size. Stage IA1 covers tumors 1 centimeter or smaller. Stage IA2 covers tumors larger than 1 centimeter but no bigger than 2 centimeters. Stage IA3 includes tumors between 2 and 3 centimeters. In all three, the cancer has not reached lymph nodes or distant sites.
For Stage IA lung cancer, current guidelines generally do not recommend PET imaging or additional invasive staging procedures beyond the initial diagnostic workup. That reflects how contained these tumors are: when the cancer is this small and localized, the likelihood of hidden spread is low enough that aggressive additional scanning isn’t considered necessary.
Stage 1A in Kidney Cancer
Kidney cancer uses a larger size threshold because the kidneys themselves are larger organs. Stage 1A means the tumor is 4 centimeters or smaller and is entirely confined within the kidney. It has not broken through the kidney’s outer capsule, has not reached lymph nodes, and has not spread elsewhere. Tumors between 4 and 7 centimeters that are still contained within the kidney are classified as Stage 1B.
Stage 1A in Ovarian Cancer
Ovarian cancer uses the FIGO staging system rather than TNM, but the principle is the same. Stage 1A means the cancer is confined to a single ovary or fallopian tube, with the outer capsule of the organ still intact. There is no tumor on the ovarian surface, and no cancer cells are found in fluid samples taken from the abdominal cavity. Once cancer appears in both ovaries or breaks through the capsule, staging advances beyond 1A.
Stage 1A in Colorectal Cancer
In the colon and rectum, staging is determined by how deeply the tumor has grown into the bowel wall rather than by overall tumor size. The bowel wall has several distinct layers. Stage 1A (T1, N0, M0) means the cancer has grown through the innermost lining and into the second layer, called the submucosa, but has not penetrated any deeper. No lymph nodes are involved and there is no distant spread.
Treatment at This Stage
Because Stage 1A cancers are small and localized, treatment is overwhelmingly focused on removing or destroying the tumor itself rather than treating the whole body. Surgery is the primary approach for most Stage 1A cancers. In breast cancer, this typically means removing the tumor with a margin of healthy tissue, often followed by radiation. In cervical cancer, Stage 1A1 can sometimes be treated with a minor surgical procedure that preserves fertility, while larger Stage 1A2 tumors may require a more extensive operation along with lymph node removal.
Chemotherapy is generally not part of the standard plan for Stage 1A cancers unless specific high-risk features are found in the tissue after surgery. Those features vary by cancer type but can include aggressive cell patterns or evidence that cancer cells were beginning to enter nearby blood or lymph vessels. For most patients, surgery alone or surgery plus radiation is sufficient.
Survival and Outlook
Stage 1A carries the most favorable prognosis of any cancer diagnosis. The five-year relative survival rate for female breast cancer overall is about 93%, and that number is even higher for Stage 1A specifically, since the overall figure includes all stages. Prostate cancer has an overall five-year survival of roughly 98%, again representing all stages combined. Lung cancer has a much lower overall five-year survival (around 30%), but that figure is heavily weighted by late-stage diagnoses. Patients diagnosed at Stage 1A have significantly better outcomes than that average suggests.
Keep in mind that survival statistics describe populations, not individuals. Factors like your age, overall health, the specific biology of your tumor, and how completely it can be removed all influence your personal outlook.
What Follow-Up Looks Like
After treatment for Stage 1A cancer, you enter a surveillance phase designed to catch any recurrence early. For breast cancer, a common schedule involves physical exams every three to six months for the first five years, then annually after that. Mammography typically begins about six months after radiation is completed and continues annually. For patients with certain genetic mutations or those diagnosed before age 50 with dense breast tissue, MRI screening may be added, alternating with mammography every six months.
Follow-up for other cancer types follows a similar logic: frequent visits in the first few years when recurrence risk is highest, tapering off as time passes. Your care team will also monitor for long-term treatment effects. In breast cancer, that can include bone health assessments, screening for lymphedema (arm swelling related to lymph node procedures), and physical therapy referrals if radiation causes stiffness or restricted movement. These follow-up plans are not one-size-fits-all and are adjusted based on the specifics of your diagnosis and treatment.